DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Vraylar" report has been added to ResearchAndMarkets.com's offering.
Vraylar (cariprazine; Gedeon Richter/Allergan/Mitsubishi Tanabe) is a novel atypical antipsychotic with partial agonistic activity at D2 and D3 receptors, and selectivity for the D3 receptor. Vraylar is also a partial agonist at 5-HT1A receptors and an antagonist at 5-HT2A receptors. Most atypical antipsychotics have full antagonistic activity at D2 and 5-HT2A receptors, giving cariprazine a unique pharmacology among drugs in the class.
Vraylar was initially developed as a drug for schizophrenia and bipolar disorder, and is now being investigated for the adjunctive treatment of major depressive disorder (MDD) as a line extension. Allergan has so far completed a single Phase III trial in MDD, which yielded negative data. Vraylar was first approved by the US Food and Drug Administration in September 2015.
Key Topics Covered
- Drug Overview
- Product Profiles
- Vraylar: Bipolar Disorder
- Vraylar: Schizophrenia
- Vraylar: Depression
List of Figures
Figure 1: Vraylar for bipolar disorder - SWOT analysis
Figure 2: Drug assessment summary for Vraylar in bipolar disorder
Figure 3: Drug assessment summary for Vraylar in bipolar disorder
Figure 4: Vraylar for schizophrenia - SWOT analysis
Figure 5: Drug assessment summary of Vraylar for schizophrenia
Figure 6: Drug assessment summary of Vraylar for schizophrenia
Figure 7: Vraylar sales for schizophrenia across the US and five major EU markets, by country, 2017-26
Figure 8: Vraylar for depression - SWOT analysis
Figure 9: Drug assessment summary for Vraylar in depression
Figure 10: Drug assessment summary for Vraylar in depression
List of Tables
Table 1: Vraylar bipolar disorder indication approvals
Table 2: Vraylar drug profile
Table 3: Overview of key pivotal trial data for Vraylar in bipolar disorder
Table 4: Key side effects (=5%) reported in clinical trials of Vraylar monotherapy for bipolar mania
Table 5: Vraylar Phase III trials in bipolar depression
Table 6: Vraylar drug profile
Table 7: Vraylar pivotal trial data in schizophrenia
Table 8: Vraylar other late-phase trial data in schizophrenia
Table 9: Vraylar sales for schizophrenia across the US and five major EU markets, by country ($m), 2017-26
Table 10: Vraylar drug profile
Table 11: Vraylar Phase II and III data in depression
For more information about this report visit https://www.researchandmarkets.com/research/s4q4h9/vraylar?w=4
